Page last updated: 2024-12-07
glycyl-arginyl-glycyl-aspartic acid
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
glycyl-arginyl-glycyl-aspartic acid: resembles the RGD peptides; supports receptor-mediated cell adhesion; RN given refers to all (L)-isomer; RN for cpd without isomeric designation not avail 7/90 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 126679 |
MeSH ID | M0177914 |
Synonyms (11)
Synonym |
---|
grgd peptide |
97461-81-9 |
gly-arg-gly-asp |
(2s)-2-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]butanedioic acid |
glycyl-arginyl-glycyl-aspartic acid |
l-aspartic acid, n-(n-(n2-glycyl-l-arginyl)glycyl)- |
n-(n-(n2-glycyl-l-arginyl)glycyl)-l-aspartic acid |
DTXSID40913908 |
n-[2-({2-[(2-amino-1-hydroxyethylidene)amino]-5-carbamimidamido-1-hydroxypentylidene}amino)-1-hydroxyethylidene]aspartic acid |
FT-0774329 |
(s)-2-(2-((s)-2-(2-aminoacetamido)-5-guanidinopentanamido)acetamido)succinic acid |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (14)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (14.29) | 18.2507 |
2000's | 9 (64.29) | 29.6817 |
2010's | 2 (14.29) | 24.3611 |
2020's | 1 (7.14) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.38
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.38) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 14 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |